COVID-19-related complication

[키워드] 1:1 acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Admission Adult patients all-cause mortality atherosclerotic benefit cardiometabolic cardiometabolic risk factor cardiovascular cardiovascular disease caused Chronic kidney disease clinical recovery clinical status clinical trial composite endpoint coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 complications COVID-19-related complication COVID-19-related complications Critically ill Dapagliflozin diabetes double-blind Effect Efficacy Eligible patients Endpoint evaluate event Glucose heart failure Hierarchical high-risk patient High-risk patients Hospitalization hypothese IMPROVE incidence individuals with COVID-19 inhibitor International investigator-initiated kidney Kidney disease Kidney injury material morbidity and mortality multicentre multiorgan failure organ organ dysfunction Patient patient population patients hospitalized patients with COVID-19 phase III study Placebo placebo-controlled study Prevent Randomized Randomized controlled trial randomized trial reduce respiratory complication Respiratory complications Respiratory failure Safety safety profile SGLT2 inhibitor shown sodium Treatment type 2 diabete type 2 diabetes with COVID-19 worsened
[DOI] 10.1111/dom.14296 PMC 바로가기 [Article Type] Article